Search

2024 AUG 5 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Datavant, the leading health data platform company, announced its upcoming participation in the Artificial [...]

(GLOBE NEWSWIRE via COMTEX) -- - Transfusion avoidance results were comparable between SB12 and reference eculizumab-treated groups, supporting clinical efficacy between SB12 and reference eculizumab INCHEON, Korea, June 14, 2024 [...]

NEW HAVEN, Conn: Jumo Health has issued the following news release: Jumo Health--a global provider of age-appropriate, culturally relevant medical education--today announced that Kevin Aniskovich, the Company's President and CEO, [...]

NEW HAVEN, Conn., April 29, 2024 /PRNewswire/ -- Jumo Health-a global provider of age-appropriate, culturally relevant medical education-today announced that Kevin Aniskovich, the Company's President and CEO, will be moderating [...]

TOKYO -- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of ME3183, a novel [...]

Data presented underscore ELC R&D's leadership in skin longevity and its work to advance optimal skin innovation methodologies that are inclusive of ethnic differences NEW YORK, Oct. 12, 2023 /PRNewswire/ [...]

NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line [...]

2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- The Estee Lauder Companies Inc. (ELC) (NYSE: EL) shared its latest clinical research [...]

Starpharma announces on 14 Jun 2023 the presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress (EHA Congress), which was held on 8-11 Jun 2023. The scientific poster and corresponding abstract are appended. AZD0466 is a highly optimized dendrimer nanoparticle formulation of AstraZeneca's dual Bcl-2/xL inhibitor, AZD4320, which utilizes Starpharma's DEP technology and is being developed by AstraZeneca under their multi-product DEP licence with Starpharma for patients with advanced blood cancers. AZD0466 is the first candidate under Starpharma's multi-product licence with AstraZeneca whereby Starpharma is eligible to receive development, launch and sales milestones, in addition to royalties. The EHA Congress is an international haematology conference that brings together clinicians, researchers, and other industry stakeholders to showcase the latest advances in haematology clinical research. The AZD0466 clinical data presented by AstraZeneca at the EHA Congress are from the ongoing global Phase 1/2 dose escalation and expansion study in patients with advanced haematological malignancies - relapsed/refractory acute myeloid leukaemia (AML) or acute lymphocytic leukaemia (ALL) (NCT04865419). As of the poster data cutoff date, 26 patients had received above or equal to 1 dose of AZD0466 up to 3600 mg. AZD0466 continues to be well tolerated in patients with relapsed/refractory acute leukaemia, with adverse events matching expected toxicity based on data from preclinical studies, and evidence of Bcl/xL on-target anti-leukaemia clinical activity in line with preclinical models. This study continues to enrol patients at 20 international trial sites. In parallel with the ongoing study in patients with acute leukaemias, AZD0466 is also being evaluated in patients with advanced non-Hodgkin lymphoma (NCT05205161), with recruitment ongoing at over 20 sites globally. Starpharma's dendrimer drug delivery technology, known as DEP, is used to enhance the therapeutic properties of drugs to improve solubility, efficacy, pharmacokinetics, targeting, and to reduce certain toxicities. Starpharma has established partnerships with three of the world's largest pharmaceutical companies - AstraZeneca, MSD, and Genentech - and has also developed three clinical-stage anticancer products based on its DEP technology, with others in preclinical development. Original source: Starpharma, website: http://www.starpharma.com/, Copyright Starpharma Holdings Ltd 2023., joint venture; patents and technical know-how; research and development; anticancer drugs; dendrimers; diethyl phthalate; drug delivery systems; nanomaterials; AstraZeneca; Genentech; MSD; [...]

DUBLIN: Mallinckrodt plc has issued the following news release: Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies in [...]

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To [...]

SOUTH SAN FRANCISCO -- The following information was released by the Heart Failure Society of America (HFSA): Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from Cohort 4 of [...]

STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, [...]

Dublin: Research and Markets has issued the following press release: The 'Pharmacovigilance USA Congress 2023' conference has been added to ResearchAndMarkets.com's offering. 'Pharmacovigilance USA Congress 2023' After witnessing outstanding success [...]

M2 PRESSWIRE-May 2, 2023-: USA Pharmacovigilance Congress 2023: Join Industry Experts from Pharma/Biotech and Clinical Research Organisations (Boston, MA, United States - September 14-15, 2023) (C)1994-2023 M2 COMMUNICATIONS RDATE:02052023 The [...]

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the [...]

Dublin: Research and Markets has issued the following news release: The 'Pharmacovigilance Europe Congress 2023' conference has been added to ResearchAndMarkets.com's offering. After witnessing outstanding success in our previous Pharmacovigilance [...]

London: UK Parliament has issued the following written answer: Answer Lord Markham Conservative Answered on 6 March 2023 The Future of UK Clinical Research Delivery 2022-2025 implementation plan summarises the [...]

NEW YORK: Landos Biopharma, Inc. has issued the following press release: Landos Biopharma, Inc. (NASDAQ: LABP) ('Landos' or the 'Company'), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients [...]

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) ('Landos' or the 'Company'), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, [...]

2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, announced the presentation [...]

CAMBRIDGE, Mass. -- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today [...]

SAN CARLOS: Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of [...]

Bayer announced on 2 Sep 2022 that it received approval from the US Food and Drug Administration (FDA) for a label update for Kerendia (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The positive data from the pivotal Phase III FIGARO-DKD study demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D. Results from the trial were presented at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. Patients living with chronic kidney disease associated with type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. FIGARO-DKD is the first contemporary Phase III CV outcomes trial to show CV benefit in a patient population where the majority of patients was in earlier CKD stages (stages 1-2 CKD, defined as estimated glomerular filtration rate (eGFR) above or equal to 60 mL/min/1.73 sq m) with albuminuria. With the addition of these study findings, the US label now includes clinical trial data from more than 13,000 patients with CKD associated with T2D based on FIDELIO-DKD and FIGARO-DKD. Kerendia offers an alternative pathway to treating chronic kidney disease associated with type 2 diabetes by blocking mineralocorticoid receptor (MR) overactivation, which contributes to CKD progression and cardiovascular damage. Original source: Bayer, website:http://www.bayer.com/, Copyright Bayer AG 2022., regulations and rulings; research and development; finerenone; Kerendia; kidney disorder treatments; [...]

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an Upcoming [...]

RESEARCH TRIANGLE PARK, N.C.: United Therapeutics Corporation has issued the following news release: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral [...]

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented [...]

GAITHERSBURG, Jun 17, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:ALT), EQNX::TICKER_END Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle [...]

CAMBRIDGE, Jun 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:BIIB),(Shenzhen:688177.SS), EQNX::TICKER_END Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), [...]

(GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 [...]

EDISON, May 27, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:HEPA), EQNX::TICKER_END Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ('AI')-driven therapeutic drug development for [...]

London: UK Parliament has issued the following written answer: Answer Lord Kamall Answered on 20 April 2022 The Future of UK Clinical Research Delivery: 2021 to 2022 Implementation Plan sets [...]

- Research Demonstrates Safety and Tolerability, Relevant CSF Biomarker Outcomes, and Preliminary Evidence of Efficacy - Trial Sponsor BrainStorm Cell Therapeutics Plans Further Clinical Development in Progressive MS NEW YORK, [...]

(GlobeNewswire) - Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the [...]

BOSTON, Sep 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor [...]

VANCOUVER: ZYMEWORKS INC. has issued the following news release: Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2-targeted [...]

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2?targeted bispecific antibody, demonstrate promising response rates and durability in [...]

WALTHAM, Mass., Sep 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Oncxerna Therapeutics, Inc. ('OncXerna'), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to [...]

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug 31, 2021 (GLOBE NEWSWIRE via COMTEX) -- VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% [...]

SAN DIEGO: Mirati Therapeutics, Inc. has issued the following news release: Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will [...]

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso [...]

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge [...]

(GlobeNewswire) - Teleflex Incorporated (NYSE:TFX) today announced that new data from real-world clinical studies of the UroLift System for men with benign prostatic hyperplasia (BPH) will be presented at the [...]

(GlobeNewswire) - Teleflex Incorporated (NYSE:TFX) today announced that new data from real-world clinical studies of the UroLift System for men with benign prostatic hyperplasia (BPH) will be presented at the [...]

WAYNE, Jul 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- Teleflex Incorporated (NYSE:TFX) today announced that new data from real-world clinical studies of the UroLift System for men with benign prostatic [...]

(GlobeNewswire) - Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with [...]

LONDON -- The following information was released by the Association of the British Pharmaceutical Industry (ABPI): The governments of the four nations of the UK have published a joint implementation [...]

AUSTIN, Texas (PRWEB) March 24, 2021 What a year. What a ride. World Vaccine Congress is known in our industry to be one of the most thrilling vaccine events involving [...]